We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

SecuraTM ICD Clinical Evaluation Study

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00526227
First Posted: September 10, 2007
Last Update Posted: June 10, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Medtronic Bakken Research Center
  Purpose
The purpose of the Secura clinical study is to evaluate the overall system safety and clinical performance of the Secura DR Implantable Cardioverter Defibrillator (ICD)

Condition Intervention
Tachyarrhythmias Device: Implantable Cardioverter Defibrillator

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Study to Evaluate System Safety and Clinical Performance of the SecuraTM ICD

Resource links provided by NLM:


Further study details as provided by Medtronic Bakken Research Center:

Primary Outcome Measures:
  • Percentage of Subjects With an Unanticipated Serious Adverse Device Effects at 1-Month Post Implant. [ Time Frame: 1 month ]

Secondary Outcome Measures:
  • Describe System Performance [ Time Frame: 1 month ]
  • Adverse Events [ Time Frame: 1 Month ]

Enrollment: 81
Study Start Date: October 2007
Study Completion Date: October 2008
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Secura ICD implanted
Device: Implantable Cardioverter Defibrillator
Implantable Cardioverter Defibrillator will be implanted
Other Name: Secura TM

Detailed Description:

The Secura ICD is an investigational dual chamber ICD that provides atrial and ventricular tachyarrhythmia detection and therapy, cardioversion, defibrillation, dual chamber rate-responsive bradycardia pacing and diagnostics.

The study will be a prospective, non-randomized, multicenter clinical study, conducted in approximately 15 centers.

To allow for sufficient experience with the device, a maximum of 80 subjects may be implanted with the Secura device. Data will be collected at baseline (enrollment), implant, 1-, 3-, and 6- months post implant and every 6 months thereafter or until study closure (whichever occurs first), Unscheduled Follow-up visits, System Modifications, Technical Observations, Study Deviations, Study Exit, upon notification of new or updated Adverse Events and in case of death.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who have an ICD indication.
  • Patients who are geographically stable and available for follow-up at the study center for the duration of the study.
  • Patients who have signed a Medical Ethics Committee (MEC) approved Informed Consent form.

Exclusion Criteria:

  • Patients with a life expectancy less than the duration of the study.
  • Patients with medical conditions that preclude the testing required for all patients by the study protocol or that otherwise limit study participation required for all patients.
  • Patients with mechanical tricuspid heart valves.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00526227


Locations
Austria
Wels, Austria
Finland
Tampere, Finland
Germany
Goettingen, Germany
Hannover, Germany
Homburg/Saar, Germany
Kaiserslautern, Germany
Luedenscheid, Germany
Muenster, Germany
Greece
Athens, Greece
Netherlands
Breda, Netherlands
Enschede, Netherlands
Saudi Arabia
Riyadh, Saudi Arabia
Sweden
Lund, Sweden
Sponsors and Collaborators
Medtronic Bakken Research Center
Investigators
Study Chair: Secura Clinical Study Team Medtronic Bakken Research Center
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00526227     History of Changes
Other Study ID Numbers: 111
First Submitted: September 6, 2007
First Posted: September 10, 2007
Results First Submitted: January 13, 2009
Results First Posted: June 10, 2009
Last Update Posted: June 10, 2009
Last Verified: April 2009

Additional relevant MeSH terms:
Tachycardia
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes